LoginSign Up
Deep Genomics (company)

Deep Genomics (company)

A genetic medicine company that builds data driven platforms that blends synthetic biology, artificial intelligence and genetic medicine creating medical therapies.

Deep Genomics is a medical company focusing on using developing genetic based therapies. It builds artificial intelligence-driven platforms that guide the creation of new medical therapies by blending synthetic biology, artificial intelligence and genetic medicine.

Brendan Frey, Andrew Delong, Hannes Bretschneider and Hui Yuan Xiong founded Deep Genomics in 2015 in Toronto, Ontario, Canada. It has a growing team of geneticists, molecular biologists and chemists from University of Cambridge, Massachusetts Institute of Technology (MIT), Stanford University, University of Toronto, University of California, San Diego, University of Washington and University of Waterloo. It is funded by primarily by Bay Area investors and aims to develop new ways of detecting and treating disease using biologically accurate artificial intelligence technology.

Deep Genomics uses neural networks to analyze genomic data, allowing scientists to identify the genes that cause diseases and develop drugs that deal with them. It has also specialized in finding elusive and less direct disease triggers in a person’s genome. Deep learning can identify patterns in DNA that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancer and nonpolyposis colorectal cancer that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancer can identify patterns in DNA that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancer.

Project Saturn

Project Saturn is the name of Deep Genomics artificially intelligent drug prediction and design platform. The project is analyzing over 69 billion oligonucleotides against 1 million gene targets and narrowing down their results to produce 1000 potential new compounds that will work to have the predicted biological affect. The platform is able to continuously improve its predictions in a closed loop based on its failures and successes in reference to human cells. The system is designed to predict what affect an antisense oligonucleotide compound (AGO) on human cells, taking into account individual genotype and multiple biological mechanisms.

Funding

Seed

On November 18th, 2015 raised $3,700,000 in seed funding from True Ventures, Bloomberg Beta, and 11.2 Capital, and 11.2 Capital.

Series A

After completing its series A funding round on September 25th, 2017, Deep Genomics raised $13,000,000 in funding from Khosla Ventures and True Ventures.

Partnerships

Wave Life Sciences

Deep Genomics announced that it will begin working with Wave Life Sciences on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease.

Patents

Patent description
Inventor
Status
Date
App/pub number

Brendan John Frey, Andrew Thomas Delong, Hui Yuan Xiong

Application

2017-11-09

WO2017190211A1

Hui Yuan Xiong, Andrew Delong, Brendan Frey

Application

2017-01-26

US20170024642A1

Brendan Frey, Michael K.K. Leung, Andrew Thomas Delong, Hui Yuan Xiong, Babak Alipanahi, Leo J. Lee, Hannes Bretschneider

Application

2016-12-15

CA2894317A1

Timeline

Wave Life Sciences Partnership

Deep Genomics announced that it will begin working with Wave Life Sciences on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease.

Series A Funding Round

After completing its series A funding round on September 25th, 2017, Deep Genomics raised $13,000,000 in funding from Khosla Ventures and True Ventures.

Seed Funding Round

On November 18th, 2015 raised $3,700,000 in seed funding from True Ventures, Bloomberg Beta, and 11.2 Capital.

People

Name
Role
Related Golden topics

Arthur A. Levin

Advisor

Benjamin Neale

Advisor

Brendan Frey

Founder & Chief Executive Officer

Stephen Scherer

Advisor

Steven F. Dowdy

Advisor

Vern Norviel

Advisor

Vinod Khosla

Advisor ​

Yann LeCun

Advisor

Further reading

Title
Author
Link
Type

A sanctuary for startups: How an aging church became home to some of U of T's newest ventures

University of Toronto​

AI startup Deep Genomics lands financing as it aims to ‘flip medicine on its back’

Sean Silcoff

Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. - PubMed - NCBI

Kemaladewi Du, Maino E, Hyatt E, Hou H, Ding M, Place KM, Zhu X, Bassi P, Baghestani Z, Deshwar AG, Merico D, Xiong HY, Frey BJ, Wilson MD, Ivakine EA, Cohn RD

Academic paper

COSSMO: Predicting Competitive Alternative Splice Site Selection using Deep Learning

Hannes Bretschneider, Shreshth Gandhi, Khalid Zuberi, Amit Deshwar, Brendan Frey

Academic paper

Deep Genomics - MaRS Innovation

MaRS Innovation​

Deep learning of the tissue-regulated splicing code

Micheal Leung, Hui Yuan Xiong, Leo Lee, Brendan Frey

Academic paper

Genome-wide characteristics of de novo mutations in autism

Yang, L., Visel, A., Gozes, I., Francioli, L. C., Adzhubei, I. A., Sander, C., Bailey, A., Peter Szatmari, Anagnostou, E., Daniele Merico, Ronemus, M., Schotta, G., Lia D’Abate, Laird, P. W., De Rubeis, S., Yingrui Li, Henikoff, S., Carter, M. T., Wang, K., D’Gama, A. M., Bhooma Thiruvahindrapuram, Gordon, L., Yuhui Sun, Xiaomin Liu, Dong, S.

Academic paper

Inference Of The Human Polyadenylation Code

Michael Leung, Andrew Delong, Brendan Frey

Academic paper

IT pros are gearing up for AI to transform health care

Sam Charrington

Machine Learning in Genomic Medicine: A Review of Computational Problems and Data Sets - IEEE Journals & Magazine

Michael Leung, Andrew Delong, Babak Alipanahi, Brendan Frey

Academic paper

Machine Learning in Genomic Medicine: A Review of Computational Problems and Data Sets - IEEE Journals & Magazine

Michael Leung, Andrew Delong, Babak Alipanahi, Brendan Frey

Academic paper

Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning

Babak Alipanahi, Andrew Delong, Mathew Weirauch, Brendan Frey

Academic paper

The human splicing code reveals new insights into the genetic determinants of disease

Hui Xiong, Babak Alipanahi, Leo Lee, Hannes Bretscheider, Daniele Merico, Ryan Yuen, Yimin Hua, Serge Gueroussov, Hamed Najafabadi, Timothy Hughes, Quaid Morris, Yoseph Barash, Adrian Krainer, Nebojsa Jojic, Stephan Scherer, Benjamin Blencowe, Brendan Frey

Academic paper

This AI-powered genomics company is turning its attention to drug development

Will Knight

Wave Life Sciences and Deep Genomics Join Up to Splice

Ryan Black

Documentaries, videos and podcasts

Title
Date
Link

Brendan Frey - Genome Reprogramming

December 9, 2017

Brendan Frey — Deep Genomics: Changing the Course of Genomic Medicine

July 1, 2017

Companies

Company
CEO
Location
Products/Services

References